ValuEngine downgraded shares of Merus N.V. (NASDAQ:MRUS) from a hold rating to a sell rating in a report published on Monday morning.

MRUS has been the topic of several other research reports. Wedbush restated an outperform rating and set a $32.00 price objective on shares of Merus N.V. in a report on Tuesday, June 6th. Zacks Investment Research cut shares of Merus N.V. from a hold rating to a sell rating in a research report on Wednesday, June 28th. Jefferies Group LLC reiterated a buy rating and set a $31.00 price target on shares of Merus N.V. in a research note on Friday, July 14th. Finally, Royal Bank Of Canada started coverage on Merus N.V. in a research note on Thursday, September 14th. They set an outperform rating and a $28.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. Merus N.V. presently has a consensus rating of Hold and a consensus price target of $30.50.

Shares of Merus N.V. (NASDAQ MRUS) opened at 20.37 on Monday. The company’s market capitalization is $395.10 million. The firm’s 50-day moving average is $17.31 and its 200 day moving average is $17.31. Merus N.V. has a 12 month low of $13.13 and a 12 month high of $29.75.

COPYRIGHT VIOLATION NOTICE: “Merus N.V. (MRUS) Lowered to Sell at ValuEngine” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/03/merus-n-v-mrus-lowered-to-sell-at-valuengine.html.

Institutional investors have recently made changes to their positions in the company. Spark Investment Management LLC purchased a new position in shares of Merus N.V. in the 1st quarter worth about $458,000. Renaissance Technologies LLC purchased a new stake in Merus N.V. during the first quarter worth about $549,000. Iguana Healthcare Management LLC increased its holdings in Merus N.V. by 16.7% during the first quarter. Iguana Healthcare Management LLC now owns 175,000 shares of the biotechnology company’s stock worth $4,268,000 after buying an additional 25,000 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in Merus N.V. during the first quarter worth about $976,000. Finally, Wellington Management Group LLP purchased a new stake in Merus N.V. during the first quarter worth about $29,841,000. 32.16% of the stock is owned by hedge funds and other institutional investors.

Merus N.V. Company Profile

Receive News & Stock Ratings for Merus N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus N.V. and related stocks with our FREE daily email newsletter.